310 related articles for article (PubMed ID: 36871349)
1. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
5. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
6. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
7. Mutated
Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
[TBL] [Abstract][Full Text] [Related]
9. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
11. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
[TBL] [Abstract][Full Text] [Related]
12. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
13. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
[TBL] [Abstract][Full Text] [Related]
14. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
Chen K; Zhang J; Guan T; Yang F; Lou F; Chen W; Zhao M; Zhang J; Chen S; Wang J
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1123-1131.e2. PubMed ID: 28625771
[TBL] [Abstract][Full Text] [Related]
15. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
19. Comparing the efficacy of targeted next-generation sequencing in the identification of somatic mutations in circulating tumor DNA from different stages of lung cancer.
Chen Y; Han T; Zhou Y; Mao B; Zhuang W
Neoplasma; 2019 Jul; 66(4):652-660. PubMed ID: 31058536
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]